Transcriptional effects of a lupus-associated polymorphism in the 5' untranslated region (UTR) of human complement receptor 2 (CR2/CD21)

Molecular Immunology

Volumn 52, Issue 3-4, 2012, Pages 165-173

  Cruickshank, Mark N ^a,b,e   Karimi, Mahdad ^a,b   Mason, Rhonda L ^a   Fenwick, Emily ^a,b   Mercer, Tim ^a,b,f   Tsao, Betty P ^d   Boackle, Susan A ^c   Ulgiati, Daniela ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

B cells; Complement receptor 2; Gene regulation; Human; Systemic lupus erythematosus; Transcription factors

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 2; LUCIFERASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ALLELE; ARTICLE; B LYMPHOCYTE; CELL LINE; CHROMATIN; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE FREQUENCY; GENETIC TRANSFECTION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION INITIATION;

5' UNTRANSLATED REGIONS; B-LYMPHOCYTES; CELL LINE, TUMOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECEPTORS, COMPLEMENT 3D; TRANSCRIPTION, GENETIC;

EID: 84861742101     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.04.013     Document Type: Article

References (43)

1. Ahearn J.M., Fischer M.B., Croix D., Goerg S., Ma M., Xia J., Zhou X., Howard R.G., Rothstein T.L., Carroll M.C. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 1996, 4:251-262.
2. Boackle S.A., Holers V.M., Chen X., Szakonyi G., Karp D.R., Wakeland E.K., Morel L. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 2001, 15:775-785.
3. Bougel S., Renaud S., Braunschweig R., Loukinov D., Morse H.C., Bosman F.T., Lobanenkov V., Benhattar J. PAX5 activates the transcription of the human telomerase reverse transcriptase gene in B cells. Journal of Pathology 2010, 220:87-96.
4. Brasset E., Bantignies F., Court F., Cheresiz S., Conte C., Vaury C. Idefix insulator activity can be modulated by nearby regulatory elements. Nucleic Acids Research 2007, 35:2661-2670.
5. Chen Y., Dong E., Grayson D.R. Analysis of the GAD1 promoter: trans-acting factors and DNA methylation converge on the 5' untranslated region. Neuropharmacology 2011, 60:1075-1087.
6. Croix D.A., Ahearn J.M., Rosengard A.M., Han S., Kelsoe G., Ma M., Carroll M.C. Antibody response to a T-dependent antigen requires B cell expression of complement receptors. Journal of Experimental Medicine 1996, 183:1857-1864.
7. Cruickshank M., Fenwick E., Abraham L.J., Ulgiati D. Quantitative differences in chromatin accessibility across regulatory regions can be directly compared in distinct cell-types. Biochemical and Biophysical Research Communications 2008, 367:349-355.
8. Cruickshank M.N., Fenwick E., Karimi M., Abraham L.J., Ulgiati D. Cell- and stage-specific chromatin structure across the complement receptor 2 (CR2/CD21) promoter coincide with CBF1 and C/EBP-beta binding in B cells. Molecular Immunology 2009, 46:2613-2622.
9. Del Nagro C.J., Kolla R.V., Rickert R.C. A critical role for complement C3d and the B cell coreceptor (CD19/CD21) complex in the initiation of inflammatory arthritis. Journal of Immunology 2005, 175:5379-5389.
10. Douglas K.B., Windels D.C., Zhao J., Gadeliya A.V., Wu H., Kaufman K.M., Harley J.B., Merrill J., Kimberly R.P., Alarcon G.S., Brown E.E., Edberg J.C., Ramsey-Goldman R., Petri M., Reveille J.D., Vila L.M., Gaffney P.M., James J.A., Moser K.L., Alarcon-Riquelme M.E., Vyse T.J., Gilkeson G.S., Jacob C.O., Ziegler J.T., Langefeld C.D., Ulgiati D., Tsao B.P., Boackle S.A. Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing. Genes and Immunity 2009, 10:457-469.
11. Farre D., Roset R., Huerta M., Adsuara J.E., Rosello L., Alba M.M., Messeguer X. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Research 2003, 31:3651-3653.
12. Greco S.J., Smirnov S.V., Murthy R.G., Rameshwar P. Synergy between the RE-1 silencer of transcription and NFkappaB in the repression of the neurotransmitter gene TAC1 in human mesenchymal stem cells. The Journal of Biological Chemistry 2007, 282:30039-30050.
13. Haas K.M., Hasegawa M., Steeber D.A., Poe J.C., Zabel M.D., Bock C.B., Karp D.R., Briles D.E., Weis J.H., Tedder T.F. Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity 2002, 17:713-723.
14. Heckman C.A., Mehew J.W., Ying G.G., Introna M., Golay J., Boxer L.M. A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells. The Journal of Biological Chemistry 2000, 275:6499-6508.
15. Heckman C.A., Wheeler M.A., Boxer L.M. Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells. Oncogene 2003, 22:7891-7899.
16. Holers V.M. Complement receptors and the shaping of the natural antibody repertoire. Springer Seminars in Immunopathology 2005, 26:405-423.
17. Karimi M., Goldie L.C., Ulgiati D., Abraham L.J. Integration site-specific transcriptional reporter gene analysis using Flp recombinase targeted cell lines. Biotechniques 2007, 42:217-224.
18. Kaya Z., Afanasyeva M., Wang Y., Dohmen K.M., Schlichting J., Tretter T., Fairweather D., Holers V.M., Rose N.R. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nature Immunology 2001, 2:739-745.
19. Kranich J., Krautler N.J., Heinen E., Polymenidou M., Bridel C., Schildknecht A., Huber C., Kosco-Vilbois M.H., Zinkernagel R., Miele G., Aguzzi A. Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8. Journal of Experimental Medicine 2008, 205:1293-1302.
20. Landa I., Ruiz-Llorente S., Montero-Conde C., Inglada-Perez L., Schiavi F., Leskela S., Pita G., Milne R., Maravall J., Ramos I., Andia V., Rodriguez-Poyo P., Jara-Albarran A., Meoro A., del Peso C., Arribas L., Iglesias P., Caballero J., Serrano J., Pico A., Pomares F., Gimenez G., Lopez-Mondejar P., Castello R., Merante-Boschin I., Pelizzo M.R., Mauricio D., Opocher G., Rodriguez-Antona C., Gonzalez-Neira A., Matias-Guiu X., Santisteban P., Robledo M. The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genetics 2009, 5:e1000637.
21. Li Y.C., Ross J., Scheppler J.A., Franza B.R. An in vitro transcription analysis of early responses of the human immunodeficiency virus type 1 long terminal repeat to different transcriptional activators. Molecular and Cellular Biology 1991, 11:1883-1893.
22. Liu Y.J., Xu J., de Bouteiller O., Parham C.L., Grouard G., Djossou O., de Saint-Vis B., Lebecque S., Banchereau J., Moore K.W. Follicular dendritic cells specifically express the long CR2/CD21 isoform. Journal of Experimental Medicine 1997, 185:165-170.
23. Makar K.W., Pham C.T., Dehoff M.H., O'Connor S.M., Jacobi S.M., Holers V.M. An intronic silencer regulates B lymphocyte cell- and stage-specific expression of the human complement receptor type 2 (CR2, CD21) gene. Journal of Immunology 1998, 160:1268-1278.
24. Makar K.W., Ulgiati D., Hagman J., Holers V.M. A site in the complement receptor 2 (CR2/CD21) silencer is necessary for lineage specific transcriptional regulation. International Immunology 2001, 13:657-664.
25. Marquart H.V., Svendsen A., Rasmussen J.M., Nielsen C.H., Junker P., Svehag S.-E., Leslie R.G.Q. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE). Clinical and Experimental Immunology 1995, 101:60-65.
26. Messeguer X., Escudero R., Farre D., Nunez O., Martinez J., Alba M.M. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 2002, 18:333-334.
27. Molina H., Holers V.M., Li B., Fang Y.-F., Mariathasan S., Goellner J., Strauss-Schoenberger J., Karr R.W., Chaplin D.D. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:3357-3361.
28. Prodeus A.P., Georg S., Shen L.-M., Pozdnyakova O.O., Chu L., Alicot E.M., Goodnow C.C., Carroll M.C. A critical role for complement in the maintenance of self-tolerance. Immunity 1998, 9:721-731.
29. Rao S., Procko E., Shannon M.F. Chromatin remodeling, measured by a novel real-time polymerase chain reaction assay, across the proximal promoter region of the IL-2 gene. Journal of Immunology 2001, 167:4494-4503.
30. Rayhel E.J., Dehoff M.H., Holers V.M. Characterization of the human complement receptor 2 (CR2, CD21) promoter reveals sequences shared with regulatory regions of other developmentally restricted B cell proteins. Journal of Immunology 1991, 146:2021-2026.
31. Southam L., Rodriguez-Lopez J., Wilkins J.M., Pombo-Suarez M., Snelling S., Gomez-Reino J.J., Chapman K., Gonzalez A., Loughlin J. An SNP in the 5'-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. Human Molecular Genetics 2007, 16:2226-2232.
32. Suryani S., Fulcher D.A., Santner-Nanan B., Nanan R., Wong M., Shaw P.J., Gibson J., Williams A., Tangye S.G. Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood 2010, 115:519-529.
33. Takahashi K., Kozono Y., Waldschmidt T.J., Quigg R.J., Baron A., Holers V.M. Mouse complement receptors type 1 (CR1; CD35) and type 2 (CR2; CD21): expression on normal B cell subpopulations and decreased levels during development of autoimmunity in MRL/lpr mice. Journal of Immunology 1997, 159:1557-1569.
34. Tan W., Wu H., Zhao J., Derber L.A., Lee D.M., Shadick N.A., Conn D.L., Smith E.A., Gersuk V.H., Nepom G.T., Moreland L.W., Furst D.E., Thompson S.D., Jonas B.L., Holers V.M., Glass D.N., Chen P.P., Bridges S.L., Weinblatt M.E., Paulus H.E., Tsao B.P. A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis. Arthritis and Rheumatism 2010, 62:2864-2875.
35. Tedder T.F., Clement L.T., Cooper M.D. Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. Journal of Immunology 1984, 133:678-683.
36. Thomas M.D., Srivastava B., Allman D. Regulation of peripheral B cell maturation. Cellular Immunology 2006, 239:92-102.
37. Tolnay M., Vereshchagina L.A., Tsokos G.C. NF-kappaB regulates the expression of the human complement receptor 2 gene. Journal of Immunology 2002, 169:6236-6243.
38. Ulgiati D., Pham C., Holers V.M. Functional analysis of the human complement receptor 2 (CR2/CD21) promoter: characterization of basal transcriptional mechanisms. Journal of Immunology 2002, 168:6279-6285.
39. Vereshchagina L.A., Tolnay M., Tsokos G.C. Multiple transcription factors regulate the inducible expression of the human complement receptor 2 promoter. Journal of Immunology 2001, 166:6156-6163.
40. Victoratos P., Kollias G. Induction of autoantibody-mediated spontaneous arthritis critically depends on follicular dendritic cells. Immunity 2009, 30:130-142.
41. Wilson J.G., Ratnoff W.D., Schur P.H., Fearon D.T. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis and Rheumatism 1986, 29:739-747.
42. Wu H., Boackle S.A., Hanvivadhanakul P., Ulgiati D., Grossman J.M., Lee Y., Shen N., Abraham L.J., Mercer T.R., Park E., Hebert L.A., Rovin B.H., Birmingham D.J., Chang D.-M., Chen C.J., McCurdy D., Badsha H.M., Thong B.Y.H., Chng H.H., Arnett F.C., Wallace D.J., Yu C.Y., Hahn B.H., Cantor R.M., Tsao B.P. Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:3961-3966.
43. Wu X., Jiang N., Deppong C., Singh J., Dolecki G., Mao D., Morel L., Molina H.D. A role for the Cr2 gene in modifying autoantibody production in systemic lupus erythematosus. Journal of Immunology 2002, 169:1587-1592.